<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/ spontaneous urticaria: analyses according to the presence or absence of angioedema</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Marcus</forename><surname>Maurer</surname></persName>
							<email>marcus.maurer@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<orgName type="institution">Allergie-Centrum-Charit e at the Charit e -Universit€ atsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Sofen</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Dermatology</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="department" key="dep3">David Geffen School of Medicine</orgName>
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Ortiz</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Novartis Pharmaceuticals Corporation</orgName>
								<address>
									<addrLine>East Hanover</addrLine>
									<region>NJ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Kianifard</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Novartis Pharmaceuticals Corporation</orgName>
								<address>
									<addrLine>East Hanover</addrLine>
									<region>NJ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Gabriel</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Novartis Pharmaceuticals Corporation</orgName>
								<address>
									<addrLine>East Hanover</addrLine>
									<region>NJ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bernstein</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Allergy Section</orgName>
								<orgName type="department" key="dep2">Division of Immunology</orgName>
								<orgName type="department" key="dep3">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep4">College of Medicine</orgName>
								<orgName type="institution">University of Cincinnati</orgName>
								<address>
									<settlement>Cincinnati</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">The ASTERIA I</orgName>
								<orgName type="institution" key="instit2">ASTERIA II and GLACIAL studies were funded by Genentech, Inc</orgName>
								<address>
									<settlement>South San Francisco</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="institution">Novartis Pharma AG</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<address>
									<settlement>San Francisco</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution">USA and Genentech, Inc</orgName>
								<address>
									<settlement>South San Francisco</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/ spontaneous urticaria: analyses according to the presence or absence of angioedema</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">CC1A676ACC0E0144E9ED9D355CCD100F</idno>
					<idno type="DOI">10.1111/jdv.14075</idno>
					<note type="submission">Received: 29 September 2016; Accepted: 22 November 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:33+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background Approximately 50% of patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report hives and angioedema; some experience hives/angioedema only.</s></p><p><s>Objective Assess omalizumab's effect on angioedema and quality of life (QoL) in subgroups with refractory CIU/CSU: those with and without angioedema.</s><s>Methods Patients received omalizumab (75, 150 or 300 mg) or placebo every 4 weeks for 12/24 weeks.</s><s>Angioedema and QoL were assessed [Urticaria Patient Daily Diary and Dermatology Quality of Life Index (DLQI)].</s><s>Subgroups were based on the presence/absence of baseline angioedema 7 days prior to randomization.</s></p><p><s>Results Patients with baseline angioedema randomized to omalizumab 300 mg had a greater reduction in mean weekly incidence of angioedema and mean number of days/week with angioedema vs. placebo at 12 and 24 weeks.</s><s>A 3.3-to 4.5-point greater mean reduction in DLQI score was achieved with omalizumab 300 mg treatment vs. placebo, above the minimal clinically important difference threshold.</s><s>Results with lower doses vs. placebo were variable.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>Compared with placebo, omalizumab 300 mg treatment over 12-24 weeks resulted in marked reduction in incidence and number of days/week with angioedema accompanied by clinically relevant improvement in QoL.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Patients with chronic idiopathic/spontaneous urticaria (CIU/ CSU) experience recurrent episodes of wheals (hives) and/or angioedema for at least 6 weeks. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref></s><s>Hives present as pruritic wheals of variable size with surrounding erythema. <ref type="bibr" target="#b1">2</ref></s><s>Individual hives are transient, typically resolving within 24 h of onset. <ref type="bibr" target="#b1">2</ref> Angioedema is characterized by rapidly occurring swellings of the lower dermis and subcutis, and often involves mucous membranes. <ref type="bibr" target="#b1">2</ref></s><s>The swellings may be erythematous or skincoloured, and sometimes painful, typically taking up to 72 h to resolve. <ref type="bibr" target="#b1">2</ref> Estimates of the proportion of patients with CIU/CSU experiencing both hives and angioedema, and those reporting either symptom in isolation vary: 33-67% of patients experience both symptoms; 29-65% experience hives only; and 1-13% experience angioedema only. <ref type="bibr" target="#b2">3</ref></s><s>6]<ref type="bibr" target="#b6">[7]</ref> In addition, the presence of angioedema in patients with CIU/CSU is associated with a prolonged disease duration, with a greater proportion remaining symptomatic beyond 1 year compared with those experiencing hives only (64-70% vs. 43-48%, respectively). <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b8">9</ref></s><s>he current first-line therapy for patients with CIU/CSU is non-sedating second-generation H 1 -antihistamines. <ref type="bibr" target="#b0">1</ref> H 1 -antihistamines provide complete symptomatic relief in &lt;50% of all cases, <ref type="bibr" target="#b2">3</ref> so there remains an unmet need for a more targeted or optimal therapy in the majority of patients.</s><s>Omalizumab, a humanized anti-immunoglobulin E monoclonal antibody, is approved by the US Food and Drug Administration (FDA) for the treatment of adults and adolescents (≥12 years of age) with CIU/CSU who remain symptomatic despite H 1 -antihistamine treatment. <ref type="bibr" target="#b9">10</ref></s><s>2]<ref type="bibr" target="#b12">[13]</ref> Omalizumab 75 mg was also shown to significantly improve these efficacy variables in the ASTERIA I trial. <ref type="bibr" target="#b10">11</ref></s><s>ngioedema is more common in patients with CIU/CSU unresponsive to treatment with up to four times the approved dose of H 1 -antihistamines compared with patients responsive to treatment (59% vs. 29%, respectively). <ref type="bibr" target="#b13">14</ref></s><s>2]<ref type="bibr" target="#b12">[13]</ref> Analyses of data from the subgroup of patients with CIU/CSU who had angioedema at baseline in these trials provide an opportunity to further investigate patient-reported angioedema and QoL with omalizumab compared with placebo.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Objective</head><p><s>The objective of the current analysis of data from the Phase III studies was to investigate patient-reported angioedema and QoL (DLQI scores) during treatment with omalizumab vs. placebo in those patients who had angioedema at baseline.</s><s>All data refer to pooled analyses of ASTERIA I, ASTERIA II and GLACIAL, unless specifically stated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>]<ref type="bibr" target="#b12">[13]</ref> Eligible patients received subcutaneous omalizumab (75, 150 or 300 mg) or placebo every 4 weeks for 24 weeks in ASTERIA I and 12 weeks in ASTERIA II. <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12</ref></s><s>In GLACIAL, patients received subcutaneous omalizumab 300 mg or placebo every 4 weeks for 24 weeks. <ref type="bibr" target="#b12">13</ref></s><s>ll three studies were conducted in accordance with Good Clinical Practice guidelines, US FDA regulations and any other national applicable laws.</s><s>All patients (or their parents/legal guardian if under 18 years of age) provided informed written consent before participation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcomes and statistical analysis</head><p><s>In all three studies, the presence of angioedema was assessed at baseline and throughout the study using the Urticaria Patient Daily Diary (UPDD; component: angioedema-'yes' or 'no').</s><s>In the current retrospective analysis, patients were subdivided according to whether or not they experienced angioedema at baseline, defined as the presence of angioedema on at least 1 day during the 7 days prior to, but not including, the day of first treatment.</s></p><p><s>Baseline demographics and patient characteristics were summarized for the subgroup of patients with angioedema at baseline and the subgroup of patients without angioedema at baseline.</s></p><p><s>For the subgroup of patients with angioedema at baseline, the number of days per week with angioedema and the proportion of patients who were angioedema-free each week were calculated from baseline to Week 12 (all three studies), and Week 24 [ASTERIA I and GLACIAL (pooled)], based on information entered in the UPDD.</s><s>The proportion of angioedema-free days was calculated from Week 4 to Week 12 for all three studies and from Week 4 to Week 24 for ASTERIA I and GLACIAL (pooled), and was analysed using a stratified Wilcoxon ranksum test, with baseline weight (&lt;80 kg, ≥80 kg) as the stratification variable.</s><s>Summary statistics included the mean (standard deviation; SD) number of days with angioedema with omalizumab or placebo, by week.</s></p><p><s>The change from baseline to Week 12 (weekly; all three studies) and Week 24 [weekly; ASTERIA I and GLACIAL (pooled)] in the overall DLQI score was also calculated for patients with and without angioedema at baseline.</s><s>Change from baseline in overall DLQI score was analysed using an analysis of covariance (ANCOVA) model with baseline overall DLQI score as a covariate and baseline weight (&lt;80 kg vs. ≥80 kg) as strata.</s><s>P-values and 95% confidence intervals comparing the treatment difference in least squares means with omalizumab relative to placebo were derived from the ANCOVA model.</s></p><p><s>Efficacy analyses were based on the modified intent-to-treat population (observed data), which included all randomized patients who received at least one dose of study drug, with no imputation for missing scores.</s></p><p><s>All statistical analyses were conducted using SAS, Version 9.2 (SAS Institute Inc, Cary, NC, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient characteristics and demographics</head><p><s>Overall, 460 of 975 patients (47.2%) in the pooled population experienced angioedema at baseline.</s><s>The demographics of the subgroup with baseline angioedema were similar to the subgroup without baseline angioedema (Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Positive results on the Chronic Urticaria Index TM test, as assessed by in vitro basophil histamine assay, were seen more frequently in patients with baseline angioedema compared with those without angioedema (38.4% vs. 19.7%).</s></p><p><s>By contrast, baseline clinical disease activities, including the size and number of hives, itch intensity and interference with sleep and daily activities, disease duration and QoL impairment, were similar in patients with or without baseline angioedema (Table <ref type="table" target="#tab_0">1</ref>).</s><s>There were no notable differences in previous CIU/ CSU medications, which most commonly included steroids, H 2receptor antagonists, leukotriene-receptor antagonists and immunosuppressants (Table <ref type="table" target="#tab_1">2</ref>).</s><s>Prior medical conditions occurred at similar frequencies in patients with or without angioedema and most commonly included a prior diagnosis of allergic rhinitis and asthma (Table <ref type="table" target="#tab_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Number of days per week with angioedema</head><p><s>The mean number of days per week with angioedema was reduced with omalizumab and placebo by Week 12 (Fig. <ref type="figure" target="#fig_0">1a</ref>).</s><s>At baseline, patients in the omalizumab 300 mg group experienced angioedema for a mean (SD) of 3.5 (2.2) days, falling to 0.8 (1.8) days by Week 12. Corresponding values for the omalizumab 150 mg, omalizumab 75 mg and placebo groups were as follows: 3.6 (2.1) and 1.1 (1.9); 3.8 (2.1) and 1.3 (2.2); and 3.1 (1.9) and 1.3 (1.8) days, respectively.</s></p><p><s>A reduction in the mean number of days per week with angioedema (SD) was observed in the omalizumab 300 mg group at Week 24 [ASTERIA I and GLACIAL pooled; baseline, 3.5 (2.2); Week 24, 0.6 (1.5)] and placebo group [baseline, 3.0 (1.8); Week 24: 1.0 (1.8)].</s><s>Considering the omalizumab 150 and 75 mg groups (ASTERIA I only), the mean number of days per week with angioedema with omalizumab 150 mg at baseline was 3.7 (2.0) and at Week 24 was 0.4 (1.1), and with omalizumab 75 mg at baseline was 3.8 (2.3) and at Week 24 was 2.5 (2.8) (Fig. <ref type="figure" target="#fig_0">1b</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Angioedema-free patients each week</head><p><s>A consistent reduction in the number of patients with angioedema was observed in the omalizumab groups compared with placebo.</s><s>The proportion of patients with angioedema was reduced from 100% at baseline in all groups to 26.3% in the omalizumab 300 mg group, 34.5% in the omalizumab 150 mg group, 39.2% in the omalizumab 75 mg group and 47.8% in the placebo group at Week 12 of the study (Fig. <ref type="figure" target="#fig_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Proportion of angioedema-free days</head><p><s>During Weeks 4-12, the mean (SD) proportion of angioedemafree days was higher in the omalizumab groups, significantly so with the 300 mg dose, than in the placebo group (Table <ref type="table" target="#tab_3">4</ref>).</s><s>Results were similar for Weeks 4-24 in ASTERIA I and GLA-CIAL (pooled).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>QoL (DLQI) in patients with and without baseline angioedema</head><p><s>Omalizumab treatment with 300 mg, but not 150 or 75 mg, significantly improved DLQI scores in patients with and without baseline angioedema compared with placebo (Fig. <ref type="figure" target="#fig_2">3</ref>, Table <ref type="table" target="#tab_4">5</ref>).</s><s>Patients with and without baseline angioedema showed similar improvement on DLQI scores in response to omalizumab treatment (Fig. <ref type="figure" target="#fig_2">3</ref>, Table <ref type="table" target="#tab_4">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In this post hoc analysis of pooled data from the pivotal clinical studies ASTERIA I, ASTERIA II and GLACIAL for patients with angioedema at baseline, patient-reported angioedema was reduced and QoL significantly improved with omalizumab vs. placebo, after 12 (all three studies) and 24 weeks (ASTERIA I and GLACIAL pooled) of treatment.</s><s>The greatest clinical benefit in patients with baseline angioedema was observed in the omalizumab 300 and 150 mg groups.</s><s>By contrast, omalizumab 75 mg did not generally improve outcomes over placebo.</s></p><p><s>In all groups, patients had angioedema at baseline for about 3.5 days per week; after receiving monthly doses of omalizumab 300 and 150 mg for 12 weeks, this had declined to 0.8 and 1.1 days per week, respectively, and was further reduced to 0.6 and 0.4 days per week, respectively, by 24 weeks of treatment in the pooled ASTERIA I and GLACIAL analysis.</s><s>The reduction in angioedema to around 0.5 days per week with omalizumab 150-300 mg exceeded that observed with placebo, where patients had angioedema for 1.3 and 1.0 days per week at Week 12 and Week 24, respectively, of the pooled analyses.</s><s>In the subgroup of patients with baseline angioedema, the proportion of patients who continued to report angioedema declined in the placebo group throughout the study, and accounted for only 47.8% of patients at Week 12.</s><s>The self-resolution and reduced recurrence of angioedema in a proportion of patients receiving placebo highlight the transient nature of angioedema episodes; however, a greater reduction in angioedema episodes was observed with omalizumab compared with placebo, with fewer patients reporting an angioedema episode each week with omalizumab 300 mg throughout the 12-week pooled analysis.</s><s>By Week 12, omalizumab 300 mg had reduced the proportion of patients with angioedema to 26.3%.</s></p><p><s>Omalizumab 300 mg was the only dosing regimen that was more efficacious than placebo in improving the QoL for patients with baseline angioedema.</s><s>In the pooled analyses, a 3.3-to 4.5point greater reduction in DLQI score was achieved with 12-24 weeks of omalizumab 300 mg treatment vs. placebo.</s><s>The difference in change in DLQI score between the omalizumab 300 mg and placebo groups was above the previously defined minimal clinically important difference threshold of 2.2-3.1 points, indicating a clinically meaningful benefit with omalizumab treatment; <ref type="bibr" target="#b14">15</ref>    300 mg was similar for patients without angioedema at baseline (2.6-3.6 points above that achieved with placebo).</s><s>The observation that the benefits of omalizumab on QoL were similar in both subgroups of patients is perhaps not surprising if we consider that it is likely the emotional aspect, i.e. fear/anxiety of a subsequent angioedema attack that has most impact on patient QoL.</s><s>7]<ref type="bibr" target="#b17">[18]</ref> Therefore, it would be of interest in future CIU/CSU subgroup analyses to investigate patients who have experienced angioedema vs. those who have never experienced angioedema.</s><s>In addition, studies on the minority of patients with CIU/CSU who have angioedema in isolation (i.e. in the absence of hives) are warranted.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>improvement in DLQI with omalizumab</head><p><s>13]<ref type="bibr" target="#b18">19</ref> Caution is warranted in the interpretation of the results from the ASTERIA I and GLACIAL pooled analysis for the omalizumab 75 and 150 mg groups as these dosing regimens were not included in the GLACIAL study. <ref type="bibr" target="#b12">13</ref></s><s>Indeed, the highly fluctuating burden of angioedema (measured as days per week with angioedema) observed with omalizumab 75 mg in the 24-week ASTERIA I and GLACIAL pooled data are a notable exception to the overall   observed benefit of omalizumab treatment in these post hoc analyses, and may be a result of the small sample size in the omalizumab 75 mg data set.</s><s>Additional limitations of this study include the unavoidable subjectivity of patient-reported outcomes.</s><s>Patients were assessed for the presence or absence of angioedema during a baseline period defined as the 7 days prior to randomization.</s><s>However, the transitory nature of angioedema episodes means that some patients could have been misclassified as angioedemafree and later gone on to experience angioedema; likewise, patients with angioedema during the baseline period could have been experiencing a single, self-resolving episode without recurrence during the study period.</s><s>Furthermore, facial wheals can be difficult to distinguish from angioedema, which may potentially increase the incidence of reported angioedema during the baseline assessment and therefore suggest a greater response with omalizumab than that actually achieved.</s><s>Future studies of omalizumab on angioedema should try to account for this through measurements of the site, size, severity and duration of wheals.</s></p><p><s>Omalizumab represents an important add-on treatment option for the approximately 50% of CIU/CSU cases that remain symptomatic on H 1 -antihistamine therapy. <ref type="bibr" target="#b2">3</ref></s><s>The observation that angioedema is more common in these patients compared with patients responsive to treatment highlights the importance of angioedema as a clinical marker of symptom burden in CIU/ CSU. <ref type="bibr" target="#b13">14</ref> The steady and consistently greater decline in incidence and number of days per week with angioedema with omalizumab 300 mg compared with placebo in these 12-and 24week pooled analyses, accompanied by a clinically relevant improvement in QoL, is strongly supportive of the benefit of omalizumab 300 mg in the treatment of recalcitrant CIU/CSU.</s><s>0.0001 †Number of patients with or without baseline angioedema.</s><s>‡Number of patients with data at Week 12 or Week 24.</s><s>CI, confidence interval; DLQI, Dermatology Life Quality Index; LS, least squares; OMA, omalizumab; PBO, placebo.</s><s>Modified intent-to-treat population (all patients with baseline angioedema).</s><s>The LS mean was estimated using ANCOVA model with baseline overall DLQI score as covariate, and baseline weight (&lt;80 kg vs. ≥80 kg) as strata.</s><s>P-value derived from ANCOVA model.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Number of days per week with angioedema in the baseline angioedema subgroup from baseline to (a) Week 12 in ASTERIA I, ASTERIA II and GLACIAL (pooled) and (b) to Week 24 in ASTERIA I and GLACIAL (pooled).*</s><s>*Modified intent-to-treat population (all patients with baseline angioedema).</s><s>(a) PBO, n = 85-115; OMA 75 mg, n = 49-66; OMA 150 mg, n = 55-76; OMA 300 mg, n = 156-203.</s><s>(b) PBO, n = 44-85; OMA 75 mg, n = 22-35; OMA 150 mg, n = 22-38; OMA 300 mg, n = 122-171.</s><s>Arrows indicate monthly dosing.</s><s>Note that dosing was every 4 weeks for 12 weeks in ASTERIA II.</s><s>Error bars represent the standard error of the mean.</s><s>OMA, omalizumab; PBO, placebo.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Proportion of patients with baseline angioedema who had angioedema each week from baseline to Week 12 in ASTERIA I, ASTERIA II and GLACIAL (pooled).*</s><s>*Modified intent-to-treat population (all patients with baseline angioedema).</s><s>PBO, n = 40-115; OMA 75 mg, n = 20-66; OMA 150 mg, n = 19-76; OMA 300 mg, n = 39-203.</s><s>Arrows indicate monthly dosing.</s><s>OMA, omalizumab; PBO, placebo.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Change from baseline at (a) Week 12 in ASTERIA I, ASTERIA II and GLACIAL (pooled) and (b) Week 24 in ASTERIA I and GLACIAL (pooled) on the overall DLQI score for patients with baseline angioedema.*</s><s>*Modified intent-to-treat population (all patients with baseline angioedema).</s><s>P-value derived from ANCOVA model.</s><s>Error bars represent the standard error of the mean.</s><s>DLQI, Dermatology Life Quality Index; OMA, omalizumab; PBO, placebo.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Baseline characteristics and demographics for ASTERIA I, ASTERIA II and GLACIAL (pooled) for the subgroup of patients with baseline angioedema and the subgroup of patients without baseline angioedema (all patients who received at least one dose of study drug)</s></p></div></figDesc><table><row><cell>Patients with baseline angioedema</cell><cell>Patients without baseline angioedema</cell></row><row><cell>N = 460</cell><cell>N = 515</cell></row></table><note><p><s>a n = 458; b n = 513; c n = 450; d n = 490; e n = 448; f n = 508; g Defined as largest value from Day À14 and Day À7 screening, and Day 1 visits; h Based on information collected in the UPDD; i n = 455; j n = 514; k n = 511; l n = 456; m n = 457; n n = 513; o n = 453; p n = 404; q n = 445; r n = 512.</s><s>Pooled data from the placebo and omalizumab arms.</s><s>BMI, body mass index; CIU/CSU, chronic idiopathic/spontaneous urticaria; CU, chronic urticaria; CU-Q 2 oL, Chronic Urticaria Quality of Life Questionnaire; DLQI, Dermatology Life Quality Index; EuroQoL-5D, European Quality of Life-5 Dimensions; IgE, immunoglobulin E; ISS, itch severity score; MOS, measures of sleep; SD, standard deviation; UAS, urticaria activity score; UAS7, urticaria activity score over 7 days; UPDD, Urticaria Patient Daily Diary.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Previous medications for CIU/CSU for ASTERIA I, ASTERIA II and GLACIAL (pooled) for the subgroup of patients with baseline angioedema and the subgroup of patients without baseline angioedema (all patients who received at least one dose of study drug)Pooled data from the placebo and omalizumab groups.</s><s>Previous medications for CIU/CSU presented in descending order for patients with baseline angioedema.</s><s>Multiple uses of a specific medication per patient were counted once in the frequency for the medication.</s><s>Similarly, multiple uses within a specific medication class per patient were counted once in the frequency for the medication class.</s><s>Includes concomitant medications started at any time before first treatment date.</s></p></div></figDesc><table><row><cell></cell><cell>Patients with</cell><cell>Patients without</cell></row><row><cell></cell><cell>baseline</cell><cell>baseline</cell></row><row><cell></cell><cell>angioedema</cell><cell>angioedema</cell></row><row><cell></cell><cell>N = 460</cell><cell>N = 515</cell></row><row><cell>Any medication use</cell><cell>460 (100.0)</cell><cell>515 (100.0)</cell></row><row><cell>Number previous CIU/CSU</cell><cell>5.4 (2.9)</cell><cell>4.7 (2.7)</cell></row><row><cell>medications, mean (SD)</cell><cell></cell><cell></cell></row><row><cell>Antihistamines, n (%)</cell><cell>460 (100.0)</cell><cell>514 (99.8)</cell></row><row><cell>H 2 -receptor antagonist, n (%)</cell><cell>242 (52.6)</cell><cell>230 (44.7)</cell></row><row><cell>Steroids, n (%)</cell><cell>220 (47.8)</cell><cell>226 (43.9)</cell></row><row><cell>Leukotriene-receptor</cell><cell>182 (39.6)</cell><cell>154 (29.9)</cell></row><row><cell>antagonist, n (%)</cell><cell></cell><cell></cell></row><row><cell>Immunosuppressants, n (%)</cell><cell>51 (11.1)</cell><cell>36 (7.0)</cell></row><row><cell>Other, n (%)</cell><cell>240 (52.2)</cell><cell>248 (48.2)</cell></row></table><note><p><s>CIU/CSU, chronic idiopathic/spontaneous urticaria.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Commonly reported prior medical conditions, in addition to CIU/CSU, for ASTERIA I, ASTERIA II and GLACIAL (pooled) for the subgroup of patients with baseline angioedema and the subgroup of patients without baseline angioedema (all patients who received at least one dose of study drug)</s></p></div></figDesc><table><row><cell></cell><cell>Patients with</cell><cell>Patients without</cell></row><row><cell></cell><cell>baseline</cell><cell>baseline</cell></row><row><cell></cell><cell>angioedema</cell><cell>angioedema</cell></row><row><cell></cell><cell>N = 460</cell><cell>N = 515</cell></row><row><cell>Allergic rhinitis, n (%)</cell><cell>199 (43.3)</cell><cell>229 (44.5)</cell></row><row><cell>Asthma, n (%)</cell><cell>96 (20.9)</cell><cell>135 (26.2)</cell></row><row><cell>Hypertension, n (%)</cell><cell>92 (20.0)</cell><cell>112 (21.7)</cell></row><row><cell>Hypercholesterolaemia, n (%)</cell><cell>64 (13.9)</cell><cell>78 (15.1)</cell></row><row><cell cols="3">Pooled data from the placebo and omalizumab groups. Prior medical condi-</cell></row><row><cell cols="3">tions (ever reported) occurring in more than 10% of patients in any subgroup</cell></row><row><cell cols="3">are included and are ordered by descending frequency for patients with</cell></row><row><cell>baseline angioedema.</cell><cell></cell><cell></cell></row><row><cell cols="2">CIU/CSU, chronic idiopathic/spontaneous urticaria.</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Proportion of angioedema-free days from (A) Weeks 4 to 12 in ASTERIA I, ASTERIA II and GLACIAL (pooled) and (B) Weeks 4 to 24 in ASTERIA I and GLACIAL (pooled) for patients with baseline angioedema ≥80 kg) as the stratification variable.†Number of patients with baseline angioedema.</s><s>‡Number of patients with data between Weeks 4 and 12 or Weeks 4 and 24.</s><s>Modified intent-to-treat population (all patients with baseline angioedema).</s><s>OMA, omalizumab; PBO, placebo; SE, standard error.</s></p></div></figDesc><table><row><cell>Treatment</cell><cell>N †</cell><cell>n ‡</cell><cell>Angioedema-free</cell><cell>P-value</cell></row><row><cell></cell><cell></cell><cell></cell><cell>days, mean (%) (SE)</cell><cell></cell></row><row><cell cols="4">ASTERIA I, ASTERIA II and GLACIAL (pooled)-Weeks 4-12</cell><cell></cell></row><row><cell>PBO</cell><cell>115</cell><cell>94</cell><cell>78.6 (2.4)</cell><cell></cell></row><row><cell>OMA 75 mg</cell><cell>66</cell><cell>54</cell><cell>79.0 (4.1)</cell><cell>0.1521</cell></row><row><cell>OMA 150 mg</cell><cell>76</cell><cell>64</cell><cell>80.7 (3.0)</cell><cell>0.3154</cell></row><row><cell>OMA 300 mg</cell><cell>203</cell><cell>180</cell><cell>85.9 (1.8)</cell><cell>&lt;0.0001</cell></row><row><cell cols="4">ASTERIA I and GLACIAL (pooled)-Weeks 4-24</cell><cell></cell></row><row><cell>PBO</cell><cell>85</cell><cell>66</cell><cell>81.4 (2.7)</cell><cell></cell></row><row><cell>OMA 75 mg</cell><cell>35</cell><cell>33</cell><cell>68.0 (6.4)</cell><cell>0.3718</cell></row><row><cell>OMA 150 mg</cell><cell>38</cell><cell>34</cell><cell>80.0 (4.3)</cell><cell>0.6121</cell></row><row><cell>OMA 300 mg</cell><cell>171</cell><cell>147</cell><cell>86.9 (1.9)</cell><cell>&lt;0.0001</cell></row><row><cell cols="5">P-values derived from stratified Wilcoxon rank-sum test, with baseline weight</cell></row><row><cell>(&lt;80 kg,</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5</head><label>5</label><figDesc><div><p><s>LS mean differences in the change from baseline on the overall DLQI score with omalizumab vs. placebo (95% CI) at Week 12 in ASTERIA I, ASTERIA II and GLACIAL (pooled) and Week 24 in ASTERIA I and GLACIAL (pooled) for patients with and without baseline angioedema</s></p></div></figDesc><table><row><cell></cell><cell cols="3">Patients with angioedema at baseline</cell><cell></cell><cell cols="3">Patients without angioedema at baseline</cell><cell></cell></row><row><cell></cell><cell>N †</cell><cell>n ‡</cell><cell>Treatment difference in LS mean (95% CI)</cell><cell>P-value</cell><cell>N †</cell><cell>n ‡</cell><cell>Treatment difference in LS mean</cell><cell>P-value</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(95% CI)</cell><cell></cell></row><row><cell cols="4">ASTERIA I, ASTERIA II and GLACIAL (pooled)-12 weeks</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PBO</cell><cell>115</cell><cell>87</cell><cell></cell><cell></cell><cell>127</cell><cell>108</cell><cell></cell><cell></cell></row><row><cell>OMA 75 mg</cell><cell>66</cell><cell>50</cell><cell>À1.15 (À3.33 to 1.03)</cell><cell>0.2991</cell><cell>93</cell><cell>84</cell><cell>À1.09 (À2.76 to 0.58)</cell><cell>0.1982</cell></row><row><cell>OMA 150 mg</cell><cell>76</cell><cell>55</cell><cell>À1.87 (À3.83 to 0.10)</cell><cell>0.0627</cell><cell>86</cell><cell>78</cell><cell>À2.47 (À4.19 to À0.75)</cell><cell>0.0052</cell></row><row><cell>OMA 300 mg</cell><cell>203</cell><cell>169</cell><cell>À4.49 (À5.92 to À3.06)</cell><cell>&lt;0.0001</cell><cell>209</cell><cell>192</cell><cell>À3.57 (À4.76 to À2.38)</cell><cell>&lt;0.0001</cell></row><row><cell cols="4">ASTERIA I and GLACIAL (pooled)-24 weeks</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PBO</cell><cell>85</cell><cell>47</cell><cell></cell><cell></cell><cell>78</cell><cell>60</cell><cell></cell><cell></cell></row><row><cell>OMA 75 mg</cell><cell>35</cell><cell>23</cell><cell>2.41 (À1.20 to 6.03)</cell><cell>0.1868</cell><cell>42</cell><cell>36</cell><cell>À1.78 (À3.89 to 0.32)</cell><cell>0.0962</cell></row><row><cell>OMA 150 mg</cell><cell>38</cell><cell>22</cell><cell>À0.35 (À3.83 to 3.13)</cell><cell>0.8427</cell><cell>42</cell><cell>33</cell><cell>À1.32 (À3.36 to 0.71)</cell><cell>0.1999</cell></row><row><cell>OMA 300 mg</cell><cell>171</cell><cell>133</cell><cell>À3.32 (À5.27 to À1.36)</cell><cell>0.001</cell><cell>162</cell><cell>136</cell><cell>À2.64 (À3.98 to À1.29)</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2016 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Dermatology and Venereology. JEADV 2016, 31, 1056-1063Omalizumab on QoL and angioedema in CIU/CSU</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2016 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Dermatology and Venereology.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2016 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Dermatology and Venereology.JEADV 2016, 31, 1056-1063</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We dedicate this work to our esteemed colleague Dr Sheldon Spector (13 February 1939 to 29 December 2015).</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The diagnosis and management of acute and chronic urticaria: 2014 update</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bernstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Khan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="1270" to="1277" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The EAACI/GA(2) LEN/EDF/ WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="868" to="887" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="317" to="330" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cicardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Banerji</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="602" to="616" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Urticaria and quality of life</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Grob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gaudy-Marqueste</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rev Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="47" to="51" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Urticaria: impact on quality of life and economic cost</title>
		<author>
			<persName><forename type="first">O'donnell</forename><surname>Bf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Allergy Clin North Am</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="89" to="104" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The burden of chronic hives from the US patients&apos; perspective</title>
		<author>
			<persName><forename type="first">S</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vietri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Isherwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M-M</forename><surname>Balp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Poster presented at: Academy of Managed Care Pharmacy 26th Annual Meeting and Expo</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Urticaria and angio-oedema. A review of 554 patients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Champion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Carpenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Roger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="588" to="597" />
			<date type="published" when="1969">1969</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients</title>
		<author>
			<persName><forename type="first">E</forename><surname>Toubi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kessel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Avshovich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="869" to="873" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">Xolair â (omalizumab) US prescribing information</title>
		<ptr target="http://www.gene.com/download/pdf/xolair_prescribing.pdf" />
		<imprint>
			<date type="published" when="2014-09">2014. September 2016</date>
			<biblScope unit="page">26</biblScope>
		</imprint>
	</monogr>
	<note>WWW document</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H 1 -antihistamines: a randomized, placebo-controlled study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="67" to="75" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Hsieh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="924" to="935" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ledford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ashby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="101" to="109" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria</title>
		<author>
			<persName><forename type="first">E</forename><surname>Magen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mishal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zeldin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schlesinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Proc</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="460" to="466" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria</title>
		<author>
			<persName><forename type="first">R</forename><surname>Shikiar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Harding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Leahy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Lennox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Qual Life Outcomes</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">36</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Development and construct validation of the angioedema quality of life questionnaire</title>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Groffik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="1289" to="1298" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">The Angioedema Quality of Life Questionnaire (AE-QoL) -assessment of sensitivity to change and minimal clinically important difference</title>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Peveling-Oberhag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="1203" to="1209" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Burden of illness in hereditary angioedema: a conceptual model</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bygum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Aygoren-Pursun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Beusterien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="706" to="710" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Zazzali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="370" to="377" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
